辉瑞准备隆重推出第三针，对付delta变种

[enst]

那谁谁不是说mRNA技术很容易针对病毒变异研发新疫苗吗？言犹在耳啊。

对变种的保护力也超过灭活疫苗对第一代病毒了 还不错了
另外以色列这个对变种的数据不是临床对照测试的 只是大概

 

[茶马盐铁]

多打几针多好，把缴的税赚回来点。

你缴的税早就花掉了。
现在花的是你将来要缴的税。 现在花得越开心， 将来加税加得越多。

这里不是中国， 政府花掉的钱都是要老百姓去填的。

 

[阿土仔]

delta 过气了。
现在的明星是这个：

这个我认识！这是“入”，入党的入！

 

[阿土仔]

你缴的税早就花掉了。
现在花的是你将来要缴的税。 现在花得越开心， 将来加税加得越多。

这里不是中国， 政府花掉的钱都是要老百姓去填的。

中国政府花掉的钱也是老百姓填的，当然还有政府印的......

 

[茶马盐铁]

中国政府花掉的钱也是老百姓填的，当然还有政府印的......

是吗？ 中国政府也会向人民加税？？？

 

[enst]

是吗？ 中国政府也会向人民加税？？？

引入新税需要人民同意吗 党让政府加就行了

 

[lifeisfun]

看来第二针混打莫得纳的是好事

 

[Anakin]

重要的事说三遍。重要的疫苗打三次？

 

[Jay Wang]

重要的事说三遍。重要的疫苗打三次？

每年打三针

 

[thundebay]

放感染。第二针后三个月到半年。
防重症，会很久。尚未显出问题。

英国死了那么多两针的，不知道你这个“防重症到很久”的结论是从哪篇报道推论出来的

 

[贵圈]

你要看数字
然后要看趋势
然后要看人群结构
然后要看接种率
然后要看科研
然后要看疫苗种类

最后有科学的推断。

 

[贵圈]

以色列：辉瑞可有效防重症​

2021-07-08 04:24:21大公报
字号
分享

图：以色列青少年5日接种辉瑞疫苗。\法新社

【大公报讯】据美国有线电视新闻网报道：以色列政府5日发布研究报告称，辉瑞疫苗对最早在印度发现的Delta变种新冠病毒保护力有所下降，但在预防重症方面仍有93%的有效率。该国卫生部6日再次强调，该款疫苗在预防重症方面卓有成效。
截至7日，以色列约60%人口已完成接种，为科学家研究疫苗实战成绩提供重要参考。以色列最新报告显示，在Delta变种病毒肆虐的背景下，接种两剂辉瑞疫苗的有效率从5月时的95%左右降至64%，但预防重症和住院病例的有效率仍高达93%。一支来自希伯来大学的研究团队发表声明称，目前判断Delta变种对疫苗有效性具体有多大影响为时尚早。
美国布朗大学公共卫生学院院长贾哈表示，根据现有数据，使用mRNA技术的疫苗仍然具备高度的防感染效力和防重症能力。他表示：“让我们等待更多数据，但到目前为止，如果你接种了疫苗，那就毋须担心。”
辉瑞近期与得州大学医学分部（UTMB）合作进行的一项实验室研究表明，接种两剂辉瑞疫苗引发的免疫反应，可有效保护人体免受实验室培养的Delta变种毒株及其他毒株感染。

 

[贵圈]

至今，防重症效率没有大变化。

 

[贵圈]

辉瑞疫苗在以色列的有效率数据下降 但重症保护率依旧乐观​

2021年07月05日 19:00 1358 次阅读 稿源：新浪财经 2 条评论

Ynet新闻网站援引卫生部数据报道，由于Delta变种新冠病毒传播及政府防疫限制措施放松，辉瑞-BioNTech SE疫苗在以色列预防新冠病毒感染的有效率数据显著下降。与此同时，该网站称疫苗对预防重症和住院病例的保护率下降则非常温和。以色列卫生部未立即发表评论。

数据显示，5月2日至6月5日，疫苗有效率达94.3%。6月6日——即政府取消防疫限制措施五天后——到7月初，有效率骤降至64%。报告称，对预防有症状感染的有效率也出现类似下降。
与此同时，对预防住院和重症的保护率仍然很高。5月2日至6月5日，预防住院的有效率为98.2%，而6月6日至7月3日期间的有效率为93%。疫苗对疫苗接种者中预防重症的有效率也有类似下降。
Ynet称，这些数字与卫生部数据一致，后者数据显示新增病例中许多是此前接种过疫苗的，重症病例数增加地非常缓慢。该网站称，上周五，新感染病例中有55%的人此前接种过疫苗。
继此前恢复强制要求在公共场所室内配搭口罩之外，以色列政府在考虑恢复其他防疫相关限制措施。报道称，官员们还在讨论是否建议接种第三剂疫苗。
辉瑞首席执行官Albert Bourla此前说，人们“可能”在完全接种疫苗的12 个月内需要接种第三剂新冠疫苗。
以色列是全球推动疫苗接种最有效的国家之一。该国总人口中有大约57%的人已全面接种疫苗，其中50岁以上人群的接种率达到88%。

 

[贵圈]

Pfizer says it's time for a Covid booster; FDA and CDC say not so fast​

https://www.cnn.com/profiles/maggie-fox



(CNN)Drugmaker Pfizer said Thursday it is seeing waning immunity from its coronavirus vaccine and says it is picking up its efforts to develop a booster dose that will protect people from variants.
Pfizer said it would soon publish data about a third dose of vaccine and submit it to the US Food and Drug Administration, European Medicines Agency and other regulators. The company specified it would seek FDA emergency use authorization for a booster dose in August.
But in an unusual move, two top federal agencies said Americans don't need boosters yet and said it was not up to companies alone to decide when they might be needed.
Hours after Pfizer issued its statement, the FDA and Centers for Disease and Control issued a joint statement saying Americans do not need booster shots yet.
"Americans who have been fully vaccinated do not need a booster shot at this time," they said.


Pfizer/BioNTech seek full FDA approval for their Covid-19 vaccine
In a statement to CNN on Friday, the World Health Organization said, "We don't know whether booster vaccines will be needed to maintain protection against COVID-19 until additional data is collected," adding, "limited data available on how long the protection from current doses lasts and whether an additional booster dose would be beneficial and for whom."
Pfizer and its partner BioNTech said evidence was building that people's immunity starts to wane after they have been vaccinated. The Pfizer vaccine requires two doses to provide full immunity.
"As seen in real world data released from the Israel Ministry of Health, vaccine efficacy in preventing both infection and symptomatic disease has declined six months post-vaccination, although efficacy in preventing serious illnesses remains high," Pfizer said in a statement emailed to CNN.
"Additionally, during this period the Delta variant is becoming the dominant variant in Israel as well as many other countries. These findings are consistent with an ongoing analysis from the Companies' Phase 3 study," it added.
"While protection against severe disease remained high across the full six months, a decline in efficacy against symptomatic disease over time and the continued emergence of variants are expected. Based on the totality of the data they have to date, Pfizer and BioNTech believe that a third dose may be beneficial within 6 to 12 months following the second dose to maintain highest levels of protection." It gave no further details.
The announcement could have implications across the world. The Pfizer shot is the cornerstone of vaccination programs in many countries. Two-thirds of doses delivered across the European Union were made by Pfizer, according to the European Center. In Israel, Pfizer is the only vaccine used.
Of the 158 million fully vaccinated people in the US, more than half received the Pfizer shot.


White House doubles down on Covid-19 strategy as pressure from Delta variant rises
US government officials have stressed that fully vaccinated people have a low risk of infection, even from the Delta or B.1.617.2 variant, which is more transmissible than earlier lineages of the virus.
Plus, several studies have indicated the mRNA vaccines made by Pfizer and Moderna confer longterm protection.
"FDA, CDC, and NIH (the National Institutes of Health) are engaged in a science-based, rigorous process to consider whether or when a booster might be necessary. This process takes into account laboratory data, clinical trial data, and cohort data -- which can include data from specific pharmaceutical companies, but does not rely on those data exclusively," they added.
It was a clear message to Pfizer, which has been hinting at the need for a booster shot for months.


Covid vaccines can take on new coronavirus variants, studies show

"We continue to review any new data as it becomes available and will keep the public informed. We are prepared for booster doses if and when the science demonstrates that they are needed," the CDC and FDA said in the statement.
"The United States is fortunate to have highly effective vaccines that are widely available for those aged 12 and up. People who are fully vaccinated are protected from severe disease and death, including from the variants currently circulating in the country such as Delta," the statement continued.
"People who are not vaccinated remain at risk. Virtually all COVID-19 hospitalizations and deaths are among those who are unvaccinated. We encourage Americans who have not yet been vaccinated to get vaccinated as soon as possible to protect themselves and their community."
Israel's health ministry said in a statement earlier this week that it had seen efficacy of Pfizer's vaccine drop from more than 90% to about 64% as the B.1.617.2 or Delta variant spread.


Pfizer vaccine protection takes a hit as Delta variant spreads, Israeli government says
Pfizer said research showed booster doses of its vaccine, developed with BioNTech, produced levels of neutralizing antibodies that are five to 10 times higher than what's produced after two doses.
It said it's also developing a new formulation for a booster dose that may more thoroughly protect people from new variants.
"While Pfizer and BioNTech believe a third dose of BNT162b2 has the potential to preserve the highest levels of protective efficacy against all currently known variants including Delta, the companies are remaining vigilant and are developing an updated version of the Pfizer-BioNTech COVID-19 vaccine that targets the full spike protein of the Delta variant," the company said. Current vaccines target just a piece of the spike protein -- the part of the virus it uses to attach to cells.
Get CNN Health's weekly newsletter
Sign up here to get The Results Are In with Dr. Sanjay Gupta every Tuesday from the CNN Health team.

"The first batch of the mRNA for the trial has already been manufactured at BioNTech's facility in Mainz, Germany. The Companies anticipate the clinical studies to begin in August, subject to regulatory approvals."
CNN's Ivana Kottasová contributed reporting.